Chinese Journal of Antituberculosis ›› 2019, Vol. 41 ›› Issue (11): 1160-1166.doi: 10.3969/j.issn.1000-6621.2019.11.004
• Original Articles • Previous Articles Next Articles
ZHANG Ye,LI Yuan-yuan,XU Jian,CHEN Xi,WANG Bin,FU Lei,LU Yu()
Received:
2019-07-31
Online:
2019-11-10
Published:
2019-12-05
ZHANG Ye,LI Yuan-yuan,XU Jian,CHEN Xi,WANG Bin,FU Lei,LU Yu. Preliminary study on the action mechanism of TBI-166 against drug-resistant Mycobacterium tuberculosis[J]. Chinese Journal of Antituberculosis, 2019, 41(11): 1160-1166. doi: 10.3969/j.issn.1000-6621.2019.11.004
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2019.11.004
菌株编号 | 菌株 | A1 | A2 | ΔA | CAT活性(U/104cell) | 氯法齐明耐药 | 吡法齐明耐药 |
---|---|---|---|---|---|---|---|
1 | H37Rv | 2.51 | 2.11 | 0.40 | 0.54 | 否 | 否 |
2 | 13385 | 2.45 | 2.15 | 0.30 | 0.41 | 否 | 否 |
3 | 11492 | 2.98 | 2.34 | 0.64 | 0.87 | 是 | 是 |
4 | 12657 | 2.67 | 2.07 | 0.60 | 0.81 | 是 | 是 |
5 | 13480 | 2.71 | 2.21 | 0.50 | 0.68 | 是 | 否 |
6 | 13908 | 2.90 | 2.20 | 0.70 | 0.95 | 是 | 否 |
7 | 14470 | 2.88 | 2.25 | 0.63 | 0.85 | 是 | 是 |
8 | 14907 | 2.95 | 2.15 | 0.80 | 1.08 | 是 | 是 |
9 | 15171 | 2.71 | 2.01 | 0.70 | 0.95 | 是 | 否 |
10 | 17851 | 2.71 | 2.12 | 0.59 | 0.80 | 是 | 是 |
[1] | 张叶, 陆宇 . 亚胺吩嗪类药物抗结核作用研究进展. 中华结核和呼吸杂志, 2019,42(2):118-121. |
[2] |
World Health Organization . Global tuberculosis report 2016. Geneva:World Health Organization, 2016.
doi: 10.1016/j.jctube.2019.100114 URL pmid: 31788557 |
[3] |
Lu Y, Zheng M, Wang B , et al. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob Agents Chemother, 2011,55(11):5185-5193.
doi: 10.1128/AAC.00699-11 URL pmid: 21844321 |
[4] |
Zhang D, Lu Y, Liu K , et al. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. J Med Chem, 2012,55(19):8409-8417.
doi: 10.1021/jm300828h URL pmid: 22931472 |
[5] |
Xu J, Wang B, Fu L , et al. In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2019, 63(5). pii:e02155-18.
doi: 10.1128/AAC.02155-18 URL pmid: 30782992 |
[6] |
Barry VC, Belton JG, Conalty ML , et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature, 1957,179(4568):1013-1015.
doi: 10.1038/1791013a0 URL pmid: 13430770 |
[7] |
Yano T, Kassovska-Bratinova S, Teh JS , et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem, 2011,286(12):10276-10287.
doi: 10.1074/jbc.M110.200501 URL pmid: 21193400 |
[8] |
Cholo MC, Steel HC, Fourie PB , et al. Clofazimine: current status and future prospects. J Antimicrob Chemother, 2012,67(2):290-298.
doi: 10.1093/jac/dkr444 URL pmid: 22020137 |
[9] |
Cholo MC, Boshoff HI, Steel HC , et al. Effects of clofazimine on potassium uptake by a Trk-deletion mutant of Mycobacterium tuberculosis. J Antimicrob Chemother, 2006,57(1):79-84.
doi: 10.1093/jac/dki409 URL pmid: 16286358 |
[10] |
Fukutomi Y, Maeda Y, Makino M . Apoptosis-inducing activity of clofazimine in macrophages. Antimicrob Agents Chemother, 2011,55(9):4000-4005.
doi: 10.1128/AAC.00434-11 URL pmid: 21690278 |
[11] |
Zhang Y, Zhu H, Fu L , et al. Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo. Antimicrob Agents Chemother, 2019, 63(7): pii:e02496-18.
doi: 10.1128/AAC.02496-18 URL pmid: 31061157 |
[12] |
李聃, 盛莉, 赵曼曼 , 等. 新型抗结核化合物TBI-166在比格犬体内的生物利用度. 国际药学研究杂志, 2015,42(2):194-198,205.
doi: 10.13220/j.cnki.jipr.2015.02.013 URL |
[13] |
Jackett PS, Aber VR, Lowrie DB . Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis. J Gen microbiol, 1978,104(1):37-45.
doi: 10.1099/00221287-104-1-37 URL pmid: 24084 |
[14] |
Van Rensburg CE, Jooné GK, O’sullivan JF , et al. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother, 1992,36(12):2729-2735.
doi: 10.1128/aac.36.12.2729 URL pmid: 1482140 |
[15] |
Ammerman NC, Swanson RV, Tapley A , et al. Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo. J Antimicrob Chemother, 2017,72(2):455-461.
doi: 10.1093/jac/dkw417 URL pmid: 27798204 |
[1] | Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 761-768. |
[2] | YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang. Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806. |
[3] | ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang. Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813. |
[4] | ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820. |
[5] | DU Wei-xin, WEI Fen, LU Jin-biao, ZHAO Ai-hua, PU Jiang, WANG Guo-zhi, XU Miao. Preliminary establishment of national reference of the freeze-dried recombinant Mycobacterium tuberculosis allergen for the bulk potency evaluation [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 826-831. |
[6] | QU Meng-jin, LIANG Zheng-min, WANG Yuan-zhi, ZHOU Xiang-mei. Research progress of carbohydrate metabolism of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 874-879. |
[7] | SUN Qing, HUANG Hai-rong, WANG Gui-rong. In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 880-884. |
[8] | SONG Yi-meng, LI Yuan-chun, HE Wen-cong, HE Ping, BAO Jing-jing, LIU Chun-fa, LIU Dong-xin, WANG Xin-yang, ZHAO Yan-lin, LI Yan-ming. Cost analysis of fluorescence PCR probe melting curve technique for the detection of Mycobacterium tuberculosis resistance in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 712-717. |
[9] | BAO Xun-di, JIANG Yue, LIANG Suo, CHENG Hong-yan, XIA Guang-xiu, WANG Chao, YE Qian, WANG Shu, WANG Qing. Analysis of the clinical isolation rate, population distribution and drug resistance of non-tuberculous mycobacteria in Anhui [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 718-724. |
[10] | ZHANG Jie, REN Yi-xuan, PAN Li-ping, ZHANG Zong-de. Application of whole genome sequencing in research of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 737-740. |
[11] | MA Jin-bao, REN Fei, ZENG Ling-cheng, CHEN Ming-wei. Analysis of drug susceptibility of 680 patients with multidrug-resistant tuberculosis in Xi’an City from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 609-613. |
[12] | Beijing Chest Hospital,Capital Medical University, Clinical Trial Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Guideline for clinical application of clofazimine in the treatment of tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 409-417. |
[13] | LI Xin-na, SHEN Xin-xin, WANG Rui-bai, DUAN Su-xia, ZHANG Rui-qing, WANG Rui-huan, BAI Xue-ding, FAN Guo-hao, WANG Jin-rong, GAO Yuan, CHEN Zi-wei, MA Xue-jun. Application value of probe-directed recombinase amplification assay in detecting MTB rpoB gene mutation [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 481-488. |
[14] | ZHANG Xing,WANG Feng-ming,LYU Xu-feng,HUA Tian-qi,ZHANG Xue-jun,JIANG Jing-yi,DING Chen-li,ZHU Wei,XIA Guo-dong,JI Jun-min,ZHAO Fei. Analysis of influencing factors of Mycobacterium tuberculosis infection in HIV/AIDS patients [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 360-365. |
[15] | ZHAO Jiao-jie,FU Lei,WANG Bin,ZHANG Lei,HU Ming-hao,LU Yu. Establishment and application of pharmacodynamics and pharmacokinetics model in vitro [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 372-379. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||